all report title image

Ataxia Market, By Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, Others (Adaptive Devices and Occupational Therapy)), By Disease Type (Friedreich\'s Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxia, Episodic Ataxia, Others (Multiple System Atrophy (MSA))), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : 24 Jun, 2026
  • Code : CMI4714
  • Pages :254
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
  • 역사적 분포 범위 : 2020 - 2024
  • 기준 연도 : 2025
  • 예상 연도 : 2026
  • 예측 기간 : 2026 - 2033
Ingographics Image

Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.

Market Dynamics

The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.

For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.

Key features of the study

  • This report provides in-depth analysis of the global ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ataxia market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market

Market Segmentation

  • By Treatment Type (Revenue, USD Bn, 2021-2033)
    • Pharmacotherapy
      • Levodopa
      • Pramipexole
      • Desvenlafaxine
      • Venlafaxine
      • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
    • Physical Therapy
    • Speech Therapy
    • Others (Adaptive Devices and Occupational Therapy)
  • By Disease Type (Revenue, USD Bn, 2021-2033)
    • Friedreich's Ataxia
    • Ataxia-telangiectasia
    • Spinocerebellar Ataxias
    • Episodic Ataxia
    • Others (Multiple System Atrophy (MSA))
  • By Distribution Channel (Revenue, USD Bn, 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region (Revenue, USD Bn, 2021-2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa
  • Key Players
    • Pfizer Inc.
    • CRISPR Therapeutics
    • Acorda Therapeutics
    • Capsida Biotherapeutics Inc.
    • Larimar Therapeutics, Inc.
    • Healx
    • Intellia Therapeutics, Inc.
    • Editas Medicine
    • bluebird bio, Inc.
    • Sanofi
    • Merck & Co., Inc.
    • Lundbeck A/S
    • Cellectis SA
    • Bio-Techne
    • GlaxoSmithKline plc
    • Allergan

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Disease Type Approval
    • Collaboration/Merge/Acquisition
    • Regulatory Landscape
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Epidemiology
    • Robust Pipeline Analysis
  4. Global Ataxia Market, By Treatment Type, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Pharmacotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
      • Segment Trends
        • Levodopa
        • Pramipexole
        • Desvenlafaxine
        • Venlafaxine
        • Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
    • Physical Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Speech Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Others (Adaptive Devices and Occupational Therapy)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  5. Global Ataxia Market, By Disease Type, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Friedreich's Ataxia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Ataxia-telangiectasia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Spinocerebellar Ataxias
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Episodic Ataxia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Others (Multiple System Atrophy (MSA))
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  6. Global Ataxia Market, By Distribution Channel, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022– 2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  7. Global Ataxia Market, By Region, 2021 – 2033, (USD Billion)
    • Introduction
      • Market Share Analysis, By Region, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For Regions, 2022–2033
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
    • Company Profile
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • CRISPR Therapeutics
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Acorda Therapeutics
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Capsida Biotherapeutics Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Larimar Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Healx
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Intellia Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Editas Medicine
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • bluebird bio, Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Sanofi
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • H. Lundbeck A/S
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Cellectis SA
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Bio-Techne
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
      • Allergan
        • Company Highlights
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.